Ceva Animal health has launched Marbox, a broad-spectrum anti-infective, based on marbofloxacin, for the rapid treatment of bovine mastitis and respiratory disorders. According to the company, Marbox effectively provides two products in one bottle because it can be used as a high dose single injection or administered at a lower dose over several days.
Ceva says mastitis and respiratory disorders currently account for around 60% of antimicrobial prescriptions. Marbox can be used intramuscularly as a single injection for the treatment of respiratory infection. Alternatively it can be used for the treatment of acute mastitis; intravenously for the first injection and then subcutaneously at a lower dose over three days. It has a milk withdrawal of just 36 hours after subcutaneous injection.
Marbox is presented in an ergonomic CLAS vial which makes for light and shock-resistant handling, resulting in fewer breakages and reduced costs. It is available in 100 and 250 vial sizes and contains 100mg marbofloxacin per ml.
Marbox can be used in combination with Meloxidyl, Ceva's new, single shot anti-inflammatory. The product joins Ceva's bovine range of anti-infectives, which includes Cevaxel, Florkem and Spectam Injectable.
For further product information contact CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at http://www.ceva.uk.com/
Zoetis has relaunched a broad spectrum intramammary treatment for clinical mastitis, as Lincocin Forte S.
For vets seeking to prescribe an alternative first-choice tube, independent mastitis authority Dr Andrew Bradley suggests it could be a logical, efficacious option, offering the combination of two active ingredients (lincomycin and neomycin) not available in other intramammary tubes.1
Zoetis points to studies which show that In combination, these have been found to have much higher efficacy than the sum of the two parts against Staphylococci aureus.2&3
The company says Lincocin Forte is effective against Gram positive and Gram negative pathogens, in particular staphylococcus, streptococcus and coliform bacteria.
In trials, the treatment produced clinical cure rates 21% higher than an ampicillin-cloxacillin comparison in undifferentiated mastitis cases. As first choice treatment for S uberis clinical mastitis, bacteriological cure rates were similar to a penicillin-streptomycin comparison.4 Against S aureus, aesculin-positive streptococci, and E coli, combined clinical-bacteriological cure rates were 175%, 32% and 21% higher respectively with Lincocin Forte S than ampicillin-cloxacillin treatment.
Zoetis vet Jude Roberts said these findings underpin the treatment's relaunch and its suitability as a first choice therapy for new clinical mastitis cases.
Lincocin Forte S is a water-based formulation, which Jude says helps achieve good distribution in the udder and can be easier to infuse that oil-based tubes, particularly into hardened quarters associated with E coli infections.
Dr Bradley adds that water-based formulation is likely to be less irritant to udder tissues than oil-based tubes, and may improve distribution. He also suggests that "not being a fluoroquinolone or 3rd/4th generation cephalosporin may also help vets fulfil their 'appropriate and justified' prescribing responsibilities."
The recommended treatment is one 10ml syringe per infected quarter at each of three consecutive milkings. Milk from treated cows can be sold for human consumption 84-hours after the last treatment.References:
The 2022 programme will include 17 education streams, covering the veterinary and nursing care of companion animals, together with a stream covering veterinary wellness, leadership and management-related topics.
Speakers include veterinary experts and leaders from around the world, and the expected 2,000+ delegates will be able to collect 14 hours of CPD over the two days.
The VET Festival will also offer a Wellness Hub offering things like yoga, movement and mindfulness sessions alongside the lectures.
There'll be a diverse commercial exhibition, with more than 60 leading veterinary suppliers, and all delegates will also have free admission to the VETFest Live Party Night.
Noel Fitzpatrick, Clinical Chair at Fitzpatrick Referrals, who launched VET Festival in 2015, said: “The last 18 months have been tough for everyone but particularly difficult for veterinary professionals, many of whom were already suffering with challenges to their well-being and mental health because of the pressures of their work.
"VET Festival is an oasis of time during which they can relax and rejuvenate themselves; experiencing continuing professional development that is uplifting and inclusive and enjoying social activities and companionship that will replenish their souls.”
Tickets for VET Festival can be bought here: https://www.vetfestival.co.uk/delegate-info/ticket-information
Fidavet has launched Surosolve, a vet wholesaler exclusive, non-prescription ear cleaner for cats and dogs.
Fidavet says the product has multiple uses for complete cat and dog ear cleaning:
Surosolve maintains healthy ears by acting as an antibacterial flush1, 2 and antibiotic potentiating agent2, 3 while contributing to restoring the normal microbiological balance of the ear canal.
According to the company, the product has already received positive feedback from veterinary practitioners that have used it: 79 per cent liked the appearance of the formulation and over 80 per cent appreciated the fragrance.
Helen Goldberg, marketing manager for Janssen Animal Health, said: "Surosolve has a unique, powerful yet non-irritant formulation, ideal for the ears of cats and dogs. This non-irritating solution with an almost neutral pH of 6.8 allows cleaning while respecting natural ear physiology.
"Surosolve also contains Tris-EDTA, which gives extra power to concurrent topical antibiotics. EDTA is a chelating agent, active in damaging the cell surfaces of bacteria, while Tris enhances the effect of EDTA by buffering the pH, ensuring the solution is not irritating to the ear and maximising the anti-bacterial effect."
Marion Lannegrace, Janssen Animal Health international product manager for Fidavet said: "The Fidavet range is only available through veterinary wholesalers because we firmly believe these products should be used only with veterinary advice. This gives clients peace of mind that their pet is receiving the best care."
For further information on Fidavet Surosolve, visit www.fidavet.com.
References:
1 Cole LK. Anatomy and physiology of the canine ear. Veterinary Dermatology, 2010, 20 (5-6), 412-4212 Cole LK, Nuttall TJ. Pseudomonas otitis. Advances in Veterinary Dermatology, Proceedings of the Fifth World Congress of Veterinary Dermatology, 2005, (5), 324-3303 Roberts NA, Gray GW, Wilkinson SC. The bactericidal action of ethylenediaminetetraacetic acid on Pseudomonas aeruginosa. Microbios, 1970, (7-8), 189-208
The RCVS has announced that it will start to accept the first applications for the new Advanced Practitioner status from the start of September.
The new accreditation status represents a 'middle tier' between veterinary surgeons holding an initial veterinary degree and RCVS Specialists and will demonstrate that the veterinary surgeon has advanced knowledge and experience in a designated field of veterinary practice.
Practising veterinary surgeons with at least five years' experience and a relevant postgraduate qualification are eligible to apply to be recognised as RCVS Advanced Practitioners. Accepted qualifications include the Certificate in Advanced Veterinary Practice (CertAVP) with a designation; the RCVS Certificate awarded up to 2012; postgraduate clinical qualifications awarded by universities or recognised awarding bodies; and other relevant clinical postgraduate master's degrees. Full details of eligible qualifications can be found at www.rcvs.org.uk/advanced
Advanced Practitioners will be expected to undertake at least 250 hours of continuing professional development (CPD) over each five-year period of accreditation, of which 125 hours should be in their designated field.
Dr Kit Sturgess is Chair of the Advanced Practitioner Assessors Panel and was involved in the development of the scheme. He said: "I am very proud that we will soon be accepting applications for the Advanced Practitioner status, just two years after the need for such an accreditation was highlighted by Professor Sir Kenneth Calman's Specialisation Working Party, set up to look at the whole specialisation framework.
"Being an Advanced Practitioner is more than just a status - it will demonstrate to members of the public and colleagues alike that a veterinary surgeon is working at an advanced level in their field and has made an ongoing commitment to career development and lifelong learning through engaging with CPD over and above the RCVS minimum requirement."
Applications from holders of the RCVS Certificate in Advanced Veterinary Practice (CertAVP) with a designation can apply from 1 September 2014 while those holding any other relevant qualifications can apply from 13 October 2014. The deadline for all applications during this first round is 30 November 2014.
Applications can be made online at www.rcvs.org.uk/advanced where further information about eligible qualifications, CPD requirements and other details can be found. The application fee for this year is £50 - from next year it will be £80. Thereafter there will be an annual fee to remain on the list (£80 by direct debit; £90 otherwise, at current rates).
All eligible applications will be assessed by the Advanced Practitioner Assessors Panel. The first list of Advanced Practitioners is due to be published, alongside the updated Specialist list, in spring 2015 subject to approval by the RCVS Education Committee in February 2015.
If accepted on to the list, practitioners will be able to use 'RCVS Advanced Practitioner in [designated field]' after their names. The accreditation and its designation will also be a primary search field on the RCVS Find a Vet practice database as well as appearing after an individual's name on the Check the Register search tool.
Once the first list has been published, the status of Advanced Practitioner will be promoted to the public.
A free webinar about Advanced Practitioner status, hosted by the Webinar Vet, will take place on Tuesday 30 September at 8.30pm. To register for the webinar visit www.thewebinarvet.com/rcvs-advanced-practitioner-status
For further advice or details about making an application for Advanced Practitioner accreditation, visit www.rcvs.org.uk/advanced or contact the Education Department on 020 7202 0791 or ap@rcvs.org.uk
The researchers, from the Dick Vet Equine Hospital, University of Edinburgh, Newcastle University, Istituto Zooprofilattico Sperimentale delle Venezie, and the University of Padova found that affected horses have major abnormalities in the structure of their neuromuscular junctions, microscopic sites of communication between nerves and muscles that are crucial for normal muscle function.
These abnormalities are believed to represent a toxin specific signature, effectively a ‘smoking gun’, for a neurotoxic enzyme termed a phospholipase A2.
Work is now underway to definitively identify the source of the toxin, in the hope that it will lead to novel treatments and improved diagnostics for this devastating disease.
The researchers think the toxin is likely to be produced by a microbe such as a bacterium or fungus growing on the horse’s pasture during the cold and dry weather which commonly precedes the disease.
Neurotoxic phospholipase A2 toxins are also present in the venom of many poisonous snakes, and there are many similarities between the signs of grass sickness and those of snake envenomation.
While there is no suggestion that venomous snakes cause grass sickness, it is hoped that some of the drugs that are currently being developed to treat and promote nerve regeneration in people paralysed by snake venoms can aid recovery of horses from grass sickness.
The researchers say that the neurotoxin most likely also causes the apparently identical diseases (termed animal dysautonomias) which affect cats, dogs, hares, rabbits, llamas, alpacas and sheep, and that their finding contradicts the previous leading hypothesis that grass sickness is a form of botulism.
This breakthrough is summarised in an editorial in the January 2025 issue of the Equine Veterinary Journal (EVJ).
The editorial, by Bruce McGorum and colleagues, looks at the implications of their article 'Equine grass sickness is associated with major abnormalities in the ultrastructure of skeletal neuromuscular junctions2".
Bruce said: “Identifying a probable cause of Equine Grass Sickness represents a significant breakthrough.
"We hope that this discovery will lead to novel treatments and improved diagnostics for this devastating condition.
"We are very grateful for the generous support we have received from horse owners, veterinary surgeons, scientists, charities and funding bodies.”
Bruce's editorial is currently available on Early View, free for 12 weeks, and will also be published in the January 2025 print issue of the EVJ.
Reference
International Cat Care has launched a competition in which veterinary practice staff are invited to take a 'selfie' of themselves with their favourite cat and upload it to the International Society of Feline Medicine (ISFM) Facebook page (www.facebook.com/ISFMcats), where cat lovers from around the world can vote for their favourite.
The Cattitude competition is designed to raising awareness of the charity's global Cat Friendly Clinic initiative.
The photograph that gets the most Facebook 'likes' will be used by the charity to help raise awareness of the Cat Friendly Clinic programme, which aims to promote the wellbeing of cats visiting or being hospitalised in a veterinary practice. Accredited Cat Friendly Clinics fulfil a set of broad criteria that show they recognise the specific needs of cats and their owners, and place cat welfare high in their practice priorities. Cat owners in turn are able to seek out clinics that have taken steps to help them overcome common barriers to clinic visits and reduce the stress of their pet.
The Cattitude competition runs from now until the 24th April. The winning staff member will receive £200 worth of John Lewis vouchers and the practice £400 worth of Thames Medical vouchers to be spent on feline-friendly equipment.
Practices may upload as many photos as they like to the Facebook page, and will be able to encourage clients to 'Like' their photos with campaign support materials which include downloadable in-clinic display posters, a series of supplied posts for their own Facebook page, written copy for their own clinic newsletter or email along with a proforma press release they can send to their local newspapers and publications.
Clinics can find more information on taking part in the Cattitude competition at www.facebook.com/ISFMcats orwww.icatcare.org/cattitude. Details of the ICC Cat Friendly Clinic initiative and accreditation can be found atwww.catfriendlyclinic.org along with a list of already-accredited vet clinics.
Avishield IB G1-13 is indicated for active immunisation of chicks to reduce the adverse effect on cilia caused by infectious bronchitis.
The vaccine is one of two targeting the IBV 793B serotype and, with the addition of this new claim, Avishield can now be administrated on broiler, broiler breeder and laying hen farms.
Avishield IB GI-13 is a lyophilisate for oculonasal suspension/use in drinking water which contains live avian infectious bronchitis virus variant strain V-173/11: 102.7-104.6 EID50.
It has an onset of immunity 10 days after vaccination and a duration of immunity of 56 days.
Johnny Wells West, poultry key account manager at Dechra Veterinary Products, said: “The new licence extension for Avishield IB G1-13 allows greater flexibility for poultry producers to protect their flocks against infectious bronchitis on broiler, broiler breeder and laying hen farms and it is welcome news for both Dechra and the poultry industry.”
For more information contact Johnny Wells West on 07584 175758 or visit http://www.dechra.co.uk/Avishield IB G1-13
Zoetis has announced that the European Commission has granted marketing authorization for Simparica™ (sarolaner) chewable tablets, a once-monthly medication for the treatment of fleas, ticks and sarcoptic mange in dogs beginning at eight weeks of age.
Dr. Balázs Capári, a Hungarian veterinary specialist in small animal medicine who participated in clinical trials of Simparica said: "The approval of Simparica gives veterinarians a new oral choice in parasite control for dogs. In my experience, Simparica has been shown to rapidly kill fleas and ticks with efficacy that persists for five weeks. Dog owners participating in the trials also reported that Simparica is very palatable; the chewable tablet was easily taken by their dogs. The convenience of a once monthly chewable tablet helps increase compliance with treatment, giving veterinarians and dog owners confidence in continuous protection."
Dr. Catherine Knupp, Executive Vice President and President, Research and Development at Zoetis, said: "At Zoetis, we focus our innovation on the most pressing needs of veterinarians, and that is what guided us to develop a new oral choice to provide dogs with persistent protection from fleas and ticks and treatment of mites that cause sarcoptic mange. Simparica is a result of the collaboration of Zoetis scientists worldwide, who share a determination to develop new medicines that deliver real value to our veterinary customers and the animals in their care. We are excited to bring this innovative medicine, Simparica, to veterinarians and dog owners across Europe."
The active substance of Simparica is sarolaner, a new ectoparasiticide in the isoxazoline class, developed by Zoetis.
Zoetis says the marketing authorization for Simparica was based on the results of field studies conducted in seven countries, involving more than 800 dogs of various breeds from at least eight weeks of age and 1.3 kg of weight. Simparica was shown to provide efficacy for at least five weeks against ticks and fleas. It demonstrated a rapid onset of action, killing fleas before they have a chance to lay eggs and can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis. It proved effective in treating sarcoptic mange, a highly contagious skin disease in dogs.
In studies, Simparica killed all four species of tick dominant in Europe (Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus) and species of flea that most frequently infect dogs in European countries (Ctenocephalides felis and Ctenocephalides canis). Simparica was well tolerated with no adverse events reported at the therapeutic dose.
Zoetis expects to launch Simparica in the EU in the first quarter of 2016. Simparica chewable tablets will be available in 5mg, 10mg, 20mg, 40mg and 80mg dosage strengths.
For more information about Simparica and full prescribing information, visit http://www.zoetis.com/products-services/companion-animals/dogs.
As part of the partnership between the two companies, anyone who takes part in one of Improve's CPD courses in 2018 will be entitled to 6 months' half-price pet insurance from Agria.
Online Bitesize CPD modules cover topics including: cardiology, ophthalmology, small animal medicine, feline medicine and exotic animals. Modules are 20, 40 or 60 minutes in length and provide veterinary professionals with interactive experiences which count toward annual CPD requirements in short convenient bursts, earning digital badges and certificates to demonstrate total CPD achieved.
Nick White, Head of Veterinary Channel at Agria, said: "We’re delighted that our partnership with Improve International will give veterinary professionals free, instant access to high-quality and engaging CPD. Not only are the modules available varied and highly relevant, the 'bitesize' nature of the training makes it extremely convenient for busy practice staff to access.
"This is a great incentive for any practices not yet working with Agria to get onboard. As well as benefitting from free CPD, practices will also be working with a specialist lifetime insurer offering 5 weeks free insurance policies and much more for clients and their pets."
For more information, contact your Agria Business Development Manager or visit: www.agriapet.co.uk/bitesize and complete the Contact Us section, using 'FREE CPD' in the subject line of the enquiry box.
Gerry, who joined North Downs in 2008, has been clinical director at the hospital since 2012.
He has published scientific literature and lectured across the world on a range of cancer subjects including lymphoma, mast cell tumours, lung tumours, insulin-producing tumours and novel anti-cancer therapies.
He also chairs and participates in a number of European oncology research projects and has a particular interest in collaborative clinical research.
Gerry said: “I’m delighted to be taking on this role, working alongside an incredibly talented and committed team.
“NDSR has achieved so much over the years, not only with cutting-edge treatments and procedures, but also with the implementation of an innovative new nursing structure, an industry-leading internship programme and being among the first veterinary hospitals to achieve a Green iiE award, to name just a few.
Talking about his main aims for the new role, Gerry said: “I want to create opportunities for our amazing team to develop into leadership roles, giving more autonomy to individual services and improving communication between services and management.
“From a care quality perspective, we always want to improve, and I look forward to harnessing innovative ideas and tools that might lead to better outcomes for pets and their families.
https://www.ndsr.co.uk.
VECCS was founded in 1974 to promote the advancement of knowledge and high standards of practice in veterinary emergency medicine and critical care.
To that end, it hosts a membership community, medical journal, monthly webinars, facility certification, wellness initiatives, a charitable arm and two annual educational conferences.
The two organisations are collaborating to raise awareness of Improve's Emergency Medicine and Surgery online learning programme.
Upon successful completion of the training and examinations, delegates can earn an ISVPS General Practitioner Certificate and a Postgraduate Certificate awarded by Harper Adams University.
Delegates cover 14 subjects and take part in three practical sessions under the guidance of specialists in preparation of real-life scenarios.
On completion, veterinary surgeons can earn 168 RACE-approved CE credits and also an ISVPS General Practitioner Certificate (GPCert) and Harper Adams Postgraduate Certificate (PgC).
Dr Charlotte French, Head of Business Development for the US at Improve Veterinary Education, said: “We are excited to partner with VECCS and to expand our global efforts in improving emergency medicine in practice.
"It is one of the most difficult areas that vets must tackle, so we are proud to be working together in building a strong foundation of knowledge so vets can approach these high-pressure situations with the right tools.”
improveinternational.com
"Great Workplaces: Raising the Bar (Elevating Skills, Culture, and Leadership)" is a series of four in-depth conversations that will tackle themes that have an impact on recruitment and retention, uncovered through the Great Workplaces by BVA accreditation scheme.
All members of the profession are welcome to join the 50-minute webinar, which will be hosted by Rob Williams, BVA President, and Dr. Kirsten Ronngren, ManyPets Consulting Veterinarian & Vet Engagement Lead.
Rob said: “Effective mentorship is the backbone of any thriving veterinary workplace.
"Whether you’re guiding others or building your own skills, strong mentoring relationships can make all the difference.
"We hope colleagues find the webinars engaging and informative. In our first session, we’ll explore the power of mentoring and work through common gaps revealed by the Great Workplaces by BVA accreditation scheme.”
https://mybva.bva.co.uk/ems-event-calendar/mentoring-matters.html
The British Small Animal Veterinary Association has announced the appointment of Dr Frances Barr as Academic Director, tasked with developing the new BSAVA postgraduate qualification in association with the Open University, ready for launch in 2012.
Frances is a European Specialist in Veterinary Diagnostic Imaging, and a double diplomat of the Royal College of Veterinary Surgeons and the European College of Veterinary Diagnostic Imaging. She has worked both in practice and as an academic, with 26 years working in Higher Education, and has a long history of working as a BSAVA volunteer, eventually taking on the presidential mantle in 2007.
BSAVA says it aims to provide the best possible educational offering to the profession, particularly to those in practice. Grant Petrie, BSAVA President, said: "Producing a postgraduate qualification is a natural progression to BSAVA's current CPD offering - there is clearly a need for it and we have a strong legacy as a provider of quality CPD. We want to make sure that the profession is served well - with a programme designed by vets for vets. As a charity with education at the core of our remit, BSAVA is best positioned to create something that will keep investing in the knowledge and talent of the profession. However, we always knew that we would need an exceptional individual to oversee the programme, and, in Frances Barr, we know we have that person."
Frances said: "This will fill a really important need. Many practitioners have a real appetite for learning more about their particular area of interest. Of course, they can currently do this with general CPD courses, but this new qualification will provide a structured and focussed learning programme which is flexible enough to fit around the busiest lifestyle, yet challenging enough to make the qualification a personal achievement, one that will be well respected by the whole profession."
She added: "The proposed new certificates in small animal medicine and surgery will comprise a combination of traditional taught courses, a wide-range of web-based material that will include interactive sessions, and workplace-based projects. This is the way forward for practitioners and will lead the profession into a more secure future."
The qualifications will be aimed primarily at the general practitioner, so they are not designed to replace the European Diploma system or aspiring to provide specialised knowledge. Instead they will be created very much for the interested, busy practitioner for whom an accredited residency programme is not an option. Grant Petrie said: "Encouraging small animal practitioners to embark on a clinically useful, challenging yet achievable, highly regarded postgraduate qualification sits very well with the BSAVA's remit to promote excellence in small animal practice through education and science."
The BSAVA postgraduate programme will launch in 2012, with more information about registration available at Congress 2011 and online from April next year. Frances Barr will begin working with the Open University and the BSAVA team in November.
The Disciplinary Committee of the Royal College of Veterinary Surgeons has postponed judgment on sanction for 12 months in the case of a Hampshire veterinary surgeon found guilty of serious professional misconduct for cumulative failures to provide adequate professional care, and insufficient regard for animal welfare whilst treating a dog.
At a hearing which concluded last Thursday, Peter Ardle MacMahon MRCVS faced a six-part charge after working as a locum for Vets Now at North End in Portsmouth where, on the night of 14/15 July 2009, he treated Wilfred, a Cocker Spaniel who had ingested broken glass along with raw mince.
The Committee found that, having decided that surgery was an appropriate treatment, Mr MacMahon had not removed the glass identified on a radiograph. Nor had he even superficially searched the stomach contents he had evacuated to check that a large piece of glass he had previously identified on the radiograph had been removed. He had also not taken adequate steps to prevent contamination of Wilfred's abdominal cavity prior to the incision to the stomach.
Mr MacMahon admitted he knew there had been considerable spillage of stomach contents into Wilfred's abdomen. The Committee found that, with this knowledge, for Mr MacMahon to use only 250ml of fluid to lavage the abdomen was inadequate. This contributed to the Spaniel developing chemical peritonitis which might have developed into septic peritonitis but for a second operation the next morning, after the dog had been returned to the care of his usual veterinary practice. The Committee also expressed concern that Mr MacMahon had failed to effectively communicate the abdominal contamination to Wilfred's usual vets when he was handed back into their care.
Taken as individual allegations, these would not, in the opinion of the Committee, constitute serious professional misconduct. However, the Committee was of the view that, taken cumulatively, the charges were proved, and therefore the treatment given to Wilfred, fell far short of the standard to be expected in the profession.
When considering mitigating and aggravating factors, the Committee accepted that Mr MacMahon and the veterinary nurse assisting him were unfamiliar with the premises in which they were working, resulting in a difficulty in locating important equipment, and there were also multiple urgent cases during the evening the operation took place. The Committee also noted that 17 months had passed since the operation, and no further complaints against Mr MacMahon had been received by the RCVS.
The Committee further took into account that Mr MacMahon had little recent experience, having returned to practising veterinary medicine in January 2009, following almost ten years spent outside the veterinary profession. During this hiatus he undertook no continuing professional development (CPD), and completed only a five-week period of supervised practice prior to re-entering the profession.
Mrs Caroline Freedman, Chairman of the Disciplinary Committee said: "The Respondent placed himself in this situation: he knew that he had been out of practice for ten years, had not done any formal CPD during that time and chose to accept an appointment to work as a locum in a sole-charge out-of-hours emergency clinic. A foremost aggravating factor is that animal welfare was adversely affected. A non-critical patient was placed at risk by the Respondent's failures."
The Committee reiterated that the purpose of sanctions was not to be punitive, but to protect animal welfare, to maintain public confidence in the profession and to maintain professional standards. "A postponement of judgment, with suitable undertakings from the Respondent, is the correct course of action," said Mrs Freedman. Mr MacMahon has subsequently signed undertakings relating to CPD in both surgical and medical disciplines, and the Committee has postponed for 12 months its judgment as to any further sanction.
The company says AI Masses will allow veterinary professionals to analyse lesions suggestive of cancer in-clinic and with a fast turnaround.
The AI technology, which has been trained by human clinical pathologists, should enable individualised treatment outcomes earlier for more cases.
Zoetis says AI Masses only needs a single round of sample preparation and the results can, at additional cost, be supplemented with an expert review from a network of specialists through Zoetis’ Virtual Laboratory.
Dr. Richard Goldstein, DVM, DACVIM, DECVIM-CA, Global Chief Medical Officer at Zoetis said: “Waiting for results can be stressful for pet owners – even more so when it involves a cancer screening.
"Our research shows that up to 75% of pet owners find abnormal results highly stressful.1
"AI Masses is yet another point-of-care capability to deliver results in-clinic, further exemplifies Zoetis’ purpose to advance care for animals, shortening anxious wait times to allow for faster care decisions that help provide the best possible outcome.”
Pre-orders will be announced for US customers in Q2 2025.
VetSurgeon.org understands AI Masses will be coming to the UK some time in 2025.
https://www.zoetisdiagnostics.com
Conducted as a multicentric international study involving board-certified veterinary dermatologists, the trial included 35 dogs with CIF in at least two paws.
Each dog acted as its own control, and was treated with systemic antibiotics, with one paw being treated with FLE and the other paw without.
Paws were allocated based on a coin toss, and the study was single blinded: the principal investigator was responsible for the assessment of lesions, and the co-investigator was responsible for administration of FLE treatment.
The dogs were assessed over an 8-week period with check-ups every 14 days.
At every check-up the paws treated with FLE showed a greater improvement than paws without FLE treatment.
The lesions were assessed and scored with the global lesion score, the pruritic visual analogue scale, a cytological scoring, and photographic documentation.
The results of the study demonstrated that FLE combined with systemic antibiotics significantly reduced the time to clinical resolution compared to antibiotics alone.
By week four, 50% of paws in the FLE group had reached clinical resolution compared to 17% in the control group.
By week eight, 88% of paws in the FLE group had healed compared to 54% in the control group.
Dr Anja Lange, DVM, Department of Dermatology, AniCura Kleintierspezialisten Augsburg GmbH, Augsburg, Germany, said: “Canine interdigital furunculosis is a challenging condition to treat that can be prolonged and frustrating.
"Having FLE as an additional management tool is very exciting, not least because it speeds up time to healing, but it also requires us to use less antibiotics.
"The use of FLE was well accepted by all of the dog owners from the study and the dogs themselves tolerated it well, showing it can be a very useful adjunct to cases in clinical practice.”
Bimeda has announced the launch of Bilovet, a new tylosin-based antibiotic for cattle and pigs.Padraig Hyland, Head of Technical Veterinary Services at Bimeda said: ''It is with great pleasure that I announce the launch of our much anticipated Bilovet 200 mg/ml solution for injection for cattle and pigs as the latest addition to Bimeda's range of essential antibiotics.
Bilovet contains Tylosin 200 mg/ml and is the second Tylosin-based injectable antibiotic to be licensed for cattle - including dairy cattle - in the UK. Bilovet is licensed in cattle for the treatment of respiratory infections, metritis, mastitis, interdigital necrobacillosis and calf diphtheria as well as a range of pig infections, including enzootic pneumonia, haemorrhagic enteritis, erysipelas, arthritis and metritis".
Bimeda's Head of Bimeda R+D, Xavier Molins said: "Bilovet is a completely new development for a product that includes a new species (cattle). Bimeda have made a significant investment in bringing Bilovet to market, including conducting new Environmental Risk Assessment studies according to current guidelines and regulations.''
For more information, ring 01248 725 400 or email: uksales@bimeda.com
Zoetis has announced the introduction of Equimidine solution in a 50% larger plastic bottle.
The company says the new 15ml multi-dose presentation, now in plastic rather than glass, offers greater safety, as well as cost-saving advantages to practices.
Equimidine, containing 10mg/ml detomidine hydrochloride and methyl parahydroxybenzoate 1 mg/ml as a preservative, is a clear solution for intravenous injection. It has sedative and analgesic properties and is indicated for use either alone or in combination with butorphanol to facilitate the handling of horses for clinical examinations, minor surgical procedures and other manipulations. It can also be used with ketamine for short duration general anaesthesia for surgical procedures such as castration.
According to the company, the new 15ml plastic bottle is more cost-effective per dose than the old 10ml glass vial. It is also safer to use as the bottle is less likely to break if accidentally dropped. The multi-dose facility involves a tightly fitted rubber bung through which a sterile needle can be inserted to withdraw each dose.
Penny McCann, Equine Product Manager, Zoetis UK Ltd, said: "The new presentation provides practical benefits for vets and the larger bottle size means the product is now even more cost-effective."
For more information, speak to your Zoetis Account Manager, refer to the SPC or contact Zoetis Customer Support on 0845 3008034.
The ProfCon Investigation Support (PCIS) service is a free, confidential listening and support service funded by the RCVS and its Mind Matters Initiative mental health project but delivered independently by VetSupport.me, an organisation that already offers general support services to veterinary surgeons and veterinary nurses.
The service is provided by a group of trained and experienced volunteers who will also be able to offer support to any veterinary surgeon or veterinary nurse who is acting as witness.
Lizzie Lockett, RCVS CEO, said: “At the RCVS we recognise that being investigated in respect of alleged professional misconduct is a very stressful and trying experience that can knock confidence and, in some cases, lead to distress amongst practitioners.
“While part of the social contract of being members of regulated and protected professions is that, when accusations around professional misconduct are made, they have to be fully investigated by a regulator to determine if there is a case to answer. As a compassionate regulator we want to make sure that individuals going through this process can access the help and support they need.
“This service is staffed by a team of brilliant volunteers who already have experience in providing help and support on matters of mental health and wellbeing and have received additional training to augment their ability to provide emotional support to vets and nurses who may be under investigation.
“In our Strategic Plan for 2020-24, one of our key ambitions is to strengthen our credentials as a compassionate regulator that acts with empathy and understanding. The ProfCon Investigation Support Service is an important step in fulfilling this ambition, and I hope that it can deliver help to the people that need it.”
David McKeown, from VetSupport, added: “Whether via a phone call, an email conversation, or a meet-up over Zoom, our team of trained volunteers, all of whom are registered vets or vet nurses themselves, will support service users through the duration of an RCVS investigation.
“Through their support we will aim to help individuals going through this process maintain good mental health and wellbeing and strive to prevent more serious issues arising. The service is completely confidential and no conversations that individuals have with our volunteers will ever be shared with anyone else, including the RCVS. Nothing will be fed back to the College nor be used as part of the investigation process. It is also completely within the individual’s control as to how much information is shared with the VetSupport volunteer. There is no obligation to disclose any information other than perhaps a first name.
“We look forward to working with the RCVS to provide this very important service. Please don’t hesitate to contact us on info@vetsupport.me or visit www.vetsupport.me to find out more about the service and meet our team of supporters.”
TwistPak bottles have a hygienic interlock at the bottom, which allows them to be connected with a twist, creating one single mixing chamber which fits in all standard vaccination devices.
Currently, freshly mixing two vaccines requires a transfer needle.
Boehringer says the TwistPak bottle simplifies the mixing process while retaining the flexibility of using the products as a monovalent or combined vaccine.
TwistPak was jointly created with the industrial design and product development company DESIGNquadrat and awarded a Red Dot Design Award 2021 in the product design category.
Eva Joras, Global Brand Manager at Boehringer Ingelheim said: “TwistPak revolutionizes how vaccines are mixed.
"The mixing platform combines the best of both worlds: the unparalleled quality and efficacy of freshly mixed vaccines with the convenience of ready-to-use solutions.
TwistPak will be globally available in all registered presentation sizes starting May this year.
VetSurgeon.org has launched a new collaborative publishing section of the website (called a wiki) in which any member of the site may publish case studies and reports, abstracts, short communications, research papers and the results of clinical audit for open discussion and review by all.
The state-of-the-art systems in use on VetSurgeon then allow all members to comment on the work submitted. Initially, it's hoped that this will stimulate valuable further debate, discussion and critical review of papers that have already been published elsewhere. However, another benefit of this system is that it enables anyone in the profession to publish their research to the veterinary community immediately, without being at the mercy of such things as the availability of space in a traditional print journal, so original work is warmly welcomed.
Arlo Guthrie, editor of VetSurgeon said: "Of course I recognise that authors still want the kudos of publication in a traditional peer reviewed journal. However, in addition to offering immediate publication, this system also opens the review process up so that everyone in the profession can participate in a completely open way. If it works, it may even come to be thought of as a more stringent and robust method of review than the traditional method. Or perhaps more likely, peer review could become a two stage process in which work is assessed by a panel of experts and then by the sort of 'open review' offered by VetSurgeon.org."
Doubtless there will be concerns about the validity of information published in this new section of VetSurgeon, primarily because it may NOT have been subject to peer review at the time of publication. Arlo said: "I don't think this is an issue. VetSurgeon members should just have a different starting point. When you read content in, say Vet Record, you can presume it's been scrutinised and read it in that context. On VetSurgeon, you should assume the opposite, and then use the tools offered by the site to judge the value of the work yourself."
Ways of assessing work published on VetSurgeon.org include:
In phase one of this project, taking place over the coming few days, all abstracts published in Veterinary Practice magazine are being uploaded to the new wiki.
Click here to visit the new VetSurgeon Wiki
The company says its Skinsights Learning Academies help support individuals and practices improve the healthcare outcomes for the 25% of dogs medicalised by skin problems in the UK.
A number of recognised industry professionals will be giving interactive, bite-sized talks at the events, including: Filippo De Bellis, Ian Wright, Jill Maddison, Sarah Warren, Rob Pope, Evelyn Maniski and Emily Robson as well as Zoetis veterinary and business consultants.
Zoetis says all the presentations will be highly practical, presented through case reviews, research, workshops and discussions. They will offer the latest information on game-changing therapeutics, best practice work-ups, effective protocols and insightful case-studies.
The sessions are limited to groups of 30 and Zoetis says places are expected to fill quickly.
To reserve your free place, visit: http://www.zoetis.co.uk/LVS2018
If you are unable to secure a seat in the theatre, headsets will be available on the day so you can listen to the lectures whilst on the stand.
The update includes a new scoring system of low, moderate or high cancer risk which replaces the original numerical HDI scores and simplifies interpretation for clinicians, making the screening process easier to communicate with pet owners.
HT Vista says the device can now categorise cancer risk levels, based on malignant probability, with a sensitivity of 90% and a negative predictive value (NPV) of 98%.
The company says this translates to a “low cancer risk” result having a malignant probability of 10% or less, allowing veterinary teams to rule out cancer of lumps and bumps without the need for invasive procedures.
The tool can also now provide alerts for some of the low-risk cases, identifying them as lipomas, sebaceus adenomas or benign epithelial masses.
Liron Levy-Hirsch DVM MRCVS, Managing Director at HT Vista, said: "I am incredibly excited to enhance our already powerful HT Vista screening tool with a new diagnostic capability, providing veterinary teams with an even more comprehensive decision-support system.
"Our screening technology has already been a game-changer in early detection, and now, with the ability to flag specific tumour types, we are taking another significant step forward.
"This advancement empowers veterinary professionals to make even more informed decisions, supports shared decision-making with pet owners, and ultimately improves patient outcomes.
"By reducing the time from suspicion to diagnosis and treatment, we can detect cancer earlier, avoid the ‘wait and see’ approach, and help save more lives."
On the other end of the scale, a “high cancer risk” result has a malignant probability of 50% or more and indicates a stronger likelihood of malignancy.
HT Vista says these cases require additional diagnostic tests for mass identification.
The company highlights a big distinction between this and other screening modalities is that it can be nurse-led.
HT Vista will be on display and there will be live demonstrations at BSAVA Congress from the 20th to the 22nd of March 2025.
https://bit.ly/ht-vista-screening-tool
Virbac Animal Health has launched Speed Leish K, a diagnostic test for canine leishmaniosis.
Speed Leish K detects antibodies directed against the kinesins of leishmania using a Kinesin Capture Complex (KCC), a complex of recombinant proteins with strong immunogenic power at all stages of infection. Virbac says that in trials the test has demonstrated 98.5% overall accuracy.*
Virbac Product Manager Simon Boulton MRCVS said: "Leishmaniosis presents a growing threat to UK dogs, particularly those which travel with their owners on holiday to regions where the disease is endemic.
"Speed Leish K should be used as part of the primary CaniLeish vaccination protocol in animals previously at risk of exposure to ensure only health animals are vaccinated. The test can also be used to screen for the disease in animals suspected to be infected."
Speed Leish K is presented in kits of two or six tests and can be stored for 24 months at room temperature.